Caring for the long-term survivor after allogeneic stem cell transplantation

Area of Science:

• Hematology
• Oncology
• Transplantation Medicine

Background:

• Allogeneic hematopoietic cell transplantation (HCT) offers curative potential but survivors face substantial long-term risks.
• Chronic health conditions are highly prevalent, affecting up to 75% of HCT survivors.
• Severe or life-threatening complications occur in over 20% of these survivors.

Purpose of the Study:

• To delineate the spectrum and burden of long-term morbidity in allogeneic HCT survivors.
• To inform healthcare providers and policymakers about the challenges faced by this patient population.
• To underscore the necessity for continuous, proactive follow-up care.

Main Methods:

• This chapter synthesizes existing literature and clinical data on HCT survivor outcomes.
• Focuses on the prevalence and types of long-term complications.
• Emphasizes the impact of these morbidities on quality of life and healthcare needs.

Main Results:

• Subsequent malignancies and cardiopulmonary compromise are significant long-term risks.
• A high prevalence of chronic health conditions (approx. 75%) is observed.
• Over 20% experience severe or life-threatening complications, highlighting a critical need for ongoing management.

Conclusions:

• Allogeneic HCT survivors require lifelong monitoring and specialized care to manage diverse and serious long-term health issues.
• Understanding the morbidity burden is essential for developing effective survivorship care models.
• Policy and clinical practice must adapt to ensure comprehensive support for HCT survivors.